A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
Overview
Development of BAFF ligand-based CAR-T cells targeting BAFF-R, BCMA, and TACI. Cells were modified using the TcBuster transposon system and maintained in G-Rex® culture vessels.
What this paper found
A chimeric antigen receptor built from the BAFF ligand gave a single T cell product the ability to engage BAFF-R, BCMA and TACI and to kill mantle cell lymphoma, acute lymphoblastic leukemia and multiple myeloma cells. The receptor was delivered without a virus, using the TcBuster transposon system, and the engineered T cells were expanded in gas-permeable rapid expansion vessels. At a 5:1 effector:target ratio, 69% of Jeko-1 and 57% of rs4;11 cells were killed, while HEK293T lines engineered to express any single BAFF receptor were lysed and parental cells were spared. Transposon copy number stayed below 10 copies per CAR-positive cell and clonal outgrowth was low. In mice, treated animals survived significantly longer in mantle cell lymphoma xenografts and carried less tumor in myeloma and leukemia models.
Note: The efficacy data come from cell line assays and mouse xenograft models, and the authors note that no head-to-head comparison was run against existing APRIL-based or scFv-based CARs.
Overall, we have demonstrated the effectiveness of a BAFF ligand-based CAR-T cells, generated using non-viral methods, in killing ALL, MCL, and MM cells in vitro and in vivo. — Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran, Nature Communications
Study details
- Authors
- Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran
- Institution
- Department of Pathology, Case Western Reserve University, Cleveland, OH, USA · Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA · Division of Pediatric Hematology/Oncology, Angie Fowler AYA Cancer Institute, UH Rainbow Babies & Children's Hospital, Cleveland, OH, USA · Luminary Therapeutics, Minneapolis, MN, USA · Bio-Techne, Minneapolis, MN, USA · Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA · Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA · Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA · Stem Cell Institute, University of Minnesota, Minneapolis, MN, USA · The Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- Journal
- Nature Communications
- Year
- 2022
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
How G-Rex® was used
T cells electroporated with TcBuster transposase mRNA and the BAFF-CAR transposon plasmid were maintained in gas-permeable rapid expansion (G-Rex®) culture vessels from Wilson Wolf. The expansion medium was CTS OpTmizer T-cell expansion SFM with 2.5% CTS Immune Cell SR, 2 mM L-glutamine, 10 mM N-acetyl-L-cysteine, 5 ng/mL IL-7 and 5 ng/mL IL-15, at 37 °C and 5% CO2. BAFF CAR-T cells were expanded for 7 days and then cryopreserved, and cells thawed from those lots kept stable surface BAFF-CAR expression for 21 days in culture.
Ecosystem products: TcBuster
Explore related
Full citation
Wong DP, Roy NK, Zhang K, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022;13(1):217.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.